(Q46640878)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

title

A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

main subject

phase II clinical trial

0 references

1 reference

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1

G K Dy

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

8

J R Jett

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

author name string

A A Miller

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

S J Mandrekar

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

M-C Aubry

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

R M Langdon

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

R F Morton

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

A A Adjei

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

publication date

8 August 2005

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

volume

16

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

5 January 2020

page(s)

1811-1816

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16087693%20AND%20SRC:MED&resulttype=core&format=json

An advance in small-cell lung cancer treatment--more or less

5 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Insulin-like growth factor-I can mediate autocrine proliferation of human small cell lung cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Bombesin-like peptides can function as autocrine growth factors in human small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Expression of the proto-oncogenes c-met and c-kit and their ligands, hepatocyte growth factor/scatter factor and stem cell factor, in SCLC cell lines and xenografts

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Optimal two-stage designs for phase II clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Nonparametric Estimation from Incomplete Observations

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Pharmacokinetics and pharmacodynamics of imatinib in a phase I trial with chronic myeloid leukemia patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Lack of c-kit exon 11 activating mutations in c-KIT/CD117-positive SCLC tumour specimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Imatinib mesylate efficiently achieves therapeutic intratumor concentrations in vivo but has limited activity in a xenograft model of small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Kit expression in small cell carcinomas of the lung: effects of chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365

Imatinib for small cell lung cancer, aiming for a target in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FANNONC%2FMDI365